{
  "actions": [
    {
      "acted_at": "2018-09-06", 
      "action_code": "Intro-H", 
      "references": [], 
      "text": "Introduced in House", 
      "type": "action"
    }, 
    {
      "acted_at": "2018-09-06", 
      "action_code": "H11100", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr6717-115", 
  "bill_type": "hr", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }
  ], 
  "congress": "115", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2018-09-06", 
  "number": "6717", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Depression Side Effect Labeling Awareness Act of 2018", 
  "sponsor": {
    "bioguide_id": "R000515", 
    "district": "1", 
    "name": "Rush, Bobby L.", 
    "state": "IL", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2018-09-06", 
  "subjects": [
    "Administrative law and regulatory procedures", 
    "Consumer affairs", 
    "Department of Health and Human Services", 
    "Drug safety, medical device, and laboratory regulation", 
    "Food and Drug Administration (FDA)", 
    "Health", 
    "Mental health"
  ], 
  "subjects_top_term": "Health", 
  "summary": null, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Depression Side Effect Labeling Awareness Act of 2018", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Depression Side Effect Labeling Awareness Act of 2018", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Depression Side Effect Labeling Awareness Act of 2018", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-04-18T16:27:07Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/hr/BILLSTATUS-115hr6717.xml"
}